The DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Open accessAbstract
Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of P. aeruginosa has become increasingly difficult due to its remarkable capacity to resist antibiotics. Strains of Pseudomonas aeruginosa are known to utilize their high levels of intrinsic and acquired resistance mechanisms to counter most antibiotics. In addition, adaptive antibiotic resistance of P. aeruginosa is a recently characterized mechanism, which includes biofilm-mediated resistance and formation of multidrug-tolerant persister cells, and is responsible for recalcitrance and relapse of infections. The discovery and development of alternative therapeutic strategies that present novel avenues against P. aeruginosa infections are increasingly demanded and gaining more and more attention. Although mostly at the preclinical stages, many recent studies have reported several innovative therapeutic technologies that have demonstrated pronounced effectiveness in fighting against drug-resistant P. aeruginosa strains. This review highlights the mechanisms of antibiotic resistance in P. aeruginosa and discusses the current state of some novel therapeutic approaches for treatment of P. aeruginosa infections that can be further explored in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acquisition of drug resistance by P. aeruginosa depends primarily on multiple intrinsic and acquired antibiotic resistance mechanisms, including the biofilm-mediated formation of resistant and multi-drug-resistant persistent cells.223”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [223]
In the citing paper
“Meanwhile, P. aeruginosa infection can also cope with antibiotic treatment by forming persistent cells or persisters, thereby preventing the synthesis of antibiotic targets.223,262,263”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [223]
In the citing paper
“P. aeruginosa have strong ability to develop natural and acquired drug resistance through various mechanisms, including the production of antibiotic inactivating enzymes or antibiotic modifying enzymes, inhibiting the penetration of the drug through the cell wall, changing the target of antibacterial action, and limiting the drug to reach its target and adaptation to the adverse environment.223”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [223]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–246 of 246
Örmälä, A.-M., & Jalasvuori, M. (2013) · Bacteriophage · doi:10.4161/bact.24219 · Cited by 103
Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease
Murphy, T. F. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328321861a · Cited by 103
Bala, A., Kumar, R. R., & Harjai, K. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.025387-0 · Cited by 103
Vieira, A., Silva, Y. J., Cunha, Â., Gomes, N. C. M., Ackermann, H.-W., & Almeida, A. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1691-x · Cited by 102
Mandsberg, L. F., Ciofu, O., Kirkby, N. S., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00428-08 · Cited by 101
Queenan, A. M., Shang, W., Flamm, R. K., & Bush, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01004-09 · Cited by 99
Pseudomonas aeruginosa tssC1 Links Type VI Secretion and Biofilm-Specific Antibiotic Resistance
Zhang, L., Hinz, A., Nadeau, J., & Mah, T. (2011) · Journal of Bacteriology · doi:10.1128/jb.00268-11 · Cited by 98
Wolter, D. J., Hanson, N. D., & Lister, P. (2004) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2004.tb09639.x · Cited by 97
Cady, K. C., White, A., Hammond, J. H., Abendroth, M. D., Karthikeyan, R. S. G., Lalitha, P., Zegans, M. E., & O’Toole, G. A. (2010) · Microbiology · doi:10.1099/mic.0.045732-0 · Cited by 95
Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Wolter, D. J., & Lister, P. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804070311 · Cited by 94
Sultana, S. T., Atci, E., Babauta, J. T., Falghoush, A. M., Snekvik, K. R., Call, D. R., & Beyenal, H. (2015) · Scientific Reports · doi:10.1038/srep14908 · Cited by 94
Park, S.-Y., Park, H. J., Moon, S. M., Park, K., Chong, Y. P., Kim, M., Kim, S., Lee, S., Kim, Y. S., Woo, J. H., et al. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-308 · Cited by 92
Iron and zinc exploitation during bacterial pathogenesis
Ma, L. M., Terwilliger, A. L., & Maresso, A. W. (2015) · Metallomics · doi:10.1039/c5mt00170f · Cited by 89
Gökalsın, B., Aksoydan, B., Erman, B., & Sesal, N. C. (2017) · Microbial Ecology · doi:10.1007/s00248-017-0949-3 · Cited by 88
Pseudomonas aeruginosa outer membrane adhesins for human respiratory mucus glycoproteins
Carnoy, C., Scharfman, A., Brussel, E. V., Lamblin, G., Ramphal, R., & Roussel, P. (1994) · Infection and Immunity · doi:10.1128/iai.62.5.1896-1900.1994 · Cited by 86
Zheng, Z., Tharmalingam, N., Liu, Q., Jayamani, E., Kim, W., Fuchs, B. B., Zhang, R., Vilcinskas, A., & Mylonakis, E. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-17 · Cited by 86
Luyt, C. E., Aubry, A., Lü, Q., Micaëlo, M., Bréchot, N., Brossier, F., Brisson, H., Rouby, J., Trouillet, J., Combes, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02109-13 · Cited by 85
Elshaer, S. L., Shaaban, M. I., Barwa, R. F., & Hassan, R. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000327 · Cited by 82
Structure and function of the porin channel
Welte, W., Nestel, U., Wacker, T., & Diederichs, K. (1995) · Kidney International · doi:10.1038/ki.1995.374 · Cited by 81
Vaccination against respiratory Pseudomonas aeruginosa infection
Grimwood, K., Kyd, J. M., Owen, S., Massa, H. M., & Cripps, A. W. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34296 · Cited by 78
Yang, F., Gu, J., Yang, L., Chen, G., Jing, H., Wang, Y., Zeng, H., Zou, Q., Lv, F., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-04029-5 · Cited by 78
Kitao, T., Lepine, F. L., Babloudi, S., Walte, F., Steinbacher, S., Maskos, K., Blaesse, M., Negri, M., Pucci, M. J., Zahler, B., et al. (2018) · mBio · doi:10.1128/mbio.02158-17 · Cited by 78
Odumosu, B. T., Adeniyi, B. A., & Chandra, R. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-29 · Cited by 77
Sultana, S. T., Call, D. R., & Beyenal, H. (2016) · npj Biofilms and Microbiomes · doi:10.1038/s41522-016-0003-0 · Cited by 73
Braz, V. S., Furlan, J. P. R., Fernandes, A. F. T., & Stehling, E. G. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw166 · Cited by 67
Shigemura, K., Osawa, K., Kato, A., Tokimatsu, I., Arakawa, S., Shirakawa, T., & Fujisawa, M. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2015.34 · Cited by 66
Pseudomonas Aeruginosa Lectins As Targets for Novel Antibacterials
Av, G., Krivozubov, M. S., Karyagina, A. S., & Al, G. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-2-29-41 · Cited by 65
OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China
Fang, Z.-L., Zhang, L., Huang, Y.-M., et al. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2013.10.027 · Cited by 61
Ochs, M. M., Bains, M., & Hancock, R. E. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1983-1985.2000 · Cited by 61
PqsA Promotes Pyoverdine Production via Biofilm Formation
Kang, D., Turner, K., & Kirienko, N. V. (2017) · Pathogens · doi:10.3390/pathogens7010003 · Cited by 61
Boll, M., Radziejewska‐Lebrecht, J., Warth, C., Krajewska-Pietrasik, D., & Mayer, H. (1994) · FEMS Immunology & Medical Microbiology · doi:10.1016/0928-8244(94)00008-5 · Cited by 59
Hächler, H., Santanam, P., & Kayser, F. H. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1254 · Cited by 59
Bell, A., Bains, M., & Hancock, R. E. W. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.21.6657-6664.1991 · Cited by 55
Emergence of NDM – 1 in the Clinical Isolates of Pseudomonas aeruginosa in India
Khajuria, A., Praharaj, A. K., Kumar, M., & Grover, N. (2013) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2013/5509.3137 · Cited by 54
Okamoto, K., Gotoh, N., & Nishino, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2696-2699.2002 · Cited by 54
Zhu, X., Shan, A., Ma, Z., Xu, W., Wang, J., Chou, S., & Cheng, B. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04830-14 · Cited by 52
Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia
Cigana, C., Bernardini, F., Facchini, M., Alcalá-Franco, B., Riva, C., Fino, I. D., Rossi, A., Ranucci, S., Misson, P., Chevalier, É., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00390-16 · Cited by 49
Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., & Plésiat, P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki030 · Cited by 44
Zhou, Y., & Peng, Y. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1231 · Cited by 43
Jyot, J., Sonawane, A., Wu, W., & Ramphal, R. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05573.x · Cited by 38
Plazomicin: an investigational therapy for the treatment of urinary tract infections
Karaiskos, I., Souli, M., & Giamarellou, H. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1095180 · Cited by 37
Effect of MexXY Overexpression on Ceftobiprole Susceptibility in Pseudomonas aeruginosa
Baum, E. Z., Crespo‐Carbone, S. M., Morrow, B. J., Davies, T. A., Foleno, B. D., He, W., Queenan, A. M., & Bush, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00018-09 · Cited by 35
Hainrichson, M., Yaniv, O., Cherniavsky, M., Nudelman, I., Shallom-Shezifi, D., Yaron, S., & Baasov, T. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-06 · Cited by 27
Starvation- and antibiotics-induced formation of persister cells in Pseudomonas aeruginosa
Mlynárčik, P., & Kolář, M. (2016) · Biomedical Papers · doi:10.5507/bp.2016.057 · Cited by 24
Doripenem (doribax), a new carbapenem antibacterial agent.
Hilas, O., Ezzo, D., & Jodlowski, T. Z. (2008) · PubMed Central · Cited by 22
Susilowati, H., Murakami, K., Yumoto, H., Amoh, T., Hirao, K., Hirota, K., Matsuo, T., & Miyake, Y. (2017) · BioMed Research International · doi:10.1155/2017/3191752 · Cited by 22
Cited by
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Bacterial Antibiotic Resistance: The Most Critical Pathogens
Mancuso, G., Midiri, A., Gerace, E., & Biondo, C. (2021) · Pathogens · doi:10.3390/pathogens10101310 · Cited by 1,332
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Pseudomonas aeruginosa Biofilms
Thi, M. T. T., Wibowo, D., & Rehm, B. H. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228671 · Cited by 911
Metadata
- Authors
- Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 37
- Issue
- 1
- Pages
- 177-192
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2903381708
- Cited by
- 2,306
- References
- 246
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.